Canine cerebral leishmaniasis: Potential role of matrix metalloproteinase-2 in the development of neurological disease

Veterinary Immunology and Immunopathology

Volumn 148, Issue 3-4, 2012, Pages 260-266

  Melo, Guilherme D ^a   Marcondes, Mary ^a   Machado, Gisele F ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Central nervous system; Cerebrospinal fluid; Inflammation; Leishmania chagasi; Zymography

Indexed keywords

GELATINASE A;

ANIMAL EXPERIMENT; ARTICLE; BRAIN INFECTION; CANINE CEREBRAL LEISHMANIASIS; CONTROLLED STUDY; DOG DISEASE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; LEISHMANIASIS; MALE; NONHUMAN; PATHOGENESIS; PROTEIN CEREBROSPINAL FLUID LEVEL; ZYMOGRAPHY;

ANIMALS; CENTRAL NERVOUS SYSTEM PROTOZOAL INFECTIONS; DISEASE PROGRESSION; DOG DISEASES; DOGS; ENZYME PRECURSORS; FEMALE; GELATINASES; LEISHMANIASIS, VISCERAL; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9;

CANIS FAMILIARIS; LEISHMANIA DONOVANI CHAGASI;

EID: 84865018159     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2012.05.007     Document Type: Article

References (49)

1. Agrawal S., Lau L., Yong V. MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 2008, 19:42-51.
2. Baneth G., Koutinas A., Solano-Gallego L., Bourdeau P., Ferrer L. Canine leishmaniasis - new concepts and insights on an expanding zoonosis. Part one. Trends Parasitol. 2008, 24:324-330.
3. Bergman R.L., Inzana K.D., Inzana T.J. Characterization of matrix metalloproteinase-2 and -9 in cerebrospinal fluid of clinically normal dogs. Am. J. Vet. Res. 2002, 63:1359-1362.
4. Brew K., Dinakarpandian D., Nagase H.T. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000, 1477:267-283.
5. Conant K., McArthur J., Griffin D., Sjulson L., Wahl L., Irani D. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann. Neurol. 1999, 46:391-398.
6. Cuevas I., Cazzulo J., Sánchez D. gp63 homologues in Trypanosoma cruzi: surface antigens with metalloprotease activity and a possible role in host cell infection. Infect. Immun. 2003, 71:5739-5749.
7. Di Terlizzi R., Platt S.R. The function, composition and analysis of cerebrospinal fluid in companion animals. Part II. Analysis. Vet. J. 2009, 180:15-32.
8. Dzwonek J., Rylski M., Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett. 2004, 567:129-135.
9. Elkington P.T.G., O'Kane C.M., Friedland J.S. The paradox of matrix metalloproteinases in infectious disease. Clin. Exp. Immunol. 2005, 142:12-20.
10. Feitosa M.M., Ikeda F.A., Bonello F.L., Ciarlini P.C., Gonçalves M.E., Lima V.M.F., Perri S.H.V. Cerebrospinal fluid (CSF) evaluation in dogs naturally infected with visceral leishmaniasis, with and without neurological symptoms. Vet. Not. 2005, 11:61-69.
11. Garcia-Alonso M., Nieto A.G., Blanco A., Requena J.M., Alonso C., Navarrete I. Presence of antibodies in the aqueous humour and cerebrospinal fluid during Leishmania infections in dogs. Pathological features at the central nervous system. Parasite Immunol. 1996, 18:539-546.
12. Grandgenett P., Otsu K., Wilson H., Wilson M., Donelson J. A function for a specific zinc metalloprotease of African trypanosomes. PLoS Pathol. 2007, 3:1432-1445.
13. Ikeda F.A., Laurenti M.D., Corbett C.E., Feitosa M.M., Machado G.F., Perry S.H.V. Histological and immunohistochemical study of the central nervous system of dogs naturally infected by Leishmania (Leishmania) chagasi. Braz. J. Vet. Res. Anim. Sci. 2007, 44:5-11.
14. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 1994, 218:325-329.
15. Kulkarni M., Olson C., Engman D.M., McGwire B.S. Trypanosoma cruzi gp63 proteins undergo stage-specific differential posttranslational modification and are important for host cell infection. Infect. Immun. 2009, 77:2193-2200.
16. Lima V.M.F., Biazzono L., Silva A.C., Correa A.P.F.L., Luvizotto M.C.R. Serological diagnosis of visceral leishmaniasis by an enzyme immunoassay using protein A in naturally infected dogs. Braz. J. Vet. Res. Anim. Sci. 2005, 25:215-218.
17. Lima V.M.F., Gonçalves M.E., Ikeda F.A., Luvizotto M.C.R., Feitosa M.M. Anti-Leishmania antibodies in cerebrospinal fluid from dogs with visceral leishmaniasis. Braz. J. Med. Biol. Res. 2003, 36:485-489.
18. Machado G.F., Melo G.D., Moraes O.C., Souza M.S., Marcondes M., Perri S.H.V., Vasconcelos R.O. Differential alterations in the activity of matrix metalloproteinases within the nervous tissue of dogs in distinct manifestations of visceral leishmaniasis. Vet. Immunol. Immunopathol. 2010, 136:340-345.
19. Makowski G.S., Ramsby M.L. Zymographic analysis of latent and activated forms of matrix metalloproteinase-2 and -9 in synovial fluid: correlation to polymorphonuclear leukocyte infiltration and in response to infection. Clin. Chim. Acta 2003, 329:77-81.
20. Mancianti F., Gramiccia M., Gradoni L., Pieri S. Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans. R. Soc. Trop. Med. Hyg. 1988, 82:566-567.
21. Marangoni N.R., Melo G.D., Moraes O.C., Souza M.S., Perri S.H.V., Machado G.F. Levels of matrix metalloproteinase-2 and -9 in the cerebrospinal fluid of dogs with visceral leishmaniasis. Parasite Immunol. 2011, 33:330-334.
22. Marcondes J.S., Feitosa F.L.F., Ikeda-Garcia F.A., Lima V., Perri S.H.V., Feitosa M.M. Evaluation of serum proteinogram of dogs naturally infected with Leishmania chagasi with and without neurological symptoms. Rev. Bras. Cienc. Vet. 2006, 13:20-24.
23. Marshall D.C.L., Wyss-Coray T., Abraham C.R. Induction of matrix metalloproteinase-2 in human immunodeficiency virus-1 glycoprotein 120 transgenic mouse brains. Neurosci. Lett. 1998, 254:97-100.
24. Mastroianni C.M., Liuzzi G.M. Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol. Med. 2007, 13:449-459.
25. McGwire B.S., Chang K.P., Engman D.M. Migration through the extracellular matrix by the parasitic protozoan Leishmania is enhanced by surface metalloprotease gp63. Infect. Immun. 2003, 71:1008-1010.
26. Melo G.D., Machado G.F. Choroid plexus involvement in dogs with spontaneous visceral leishmaniasis: a histopathological investigation. Braz. J. Vet. Pathol. 2009, 2:69-74.
27. Melo G.D., Marcondes M., Vasconcelos R.O., Machado G.F. Leukocyte entry into the CNS of Leishmania chagasi naturally infected dogs. Vet. Parasitol. 2009, 162:248-256.
28. Melo G.D., Machado G.F. Glial reactivity in dogs with visceral leishmaniasis: correlation with T lymphocyte infiltration and with cerebrospinal fluid anti-Leishmania antibody titres. Cell Tissue Res. 2011, 346:293-304.
29. Melo G., Marangoni N.R., Marcondes M., Lima V., Machado G. High levels of serum matrix metalloproteinases in dogs with natural visceral leishmaniasis: a preliminary report. Vet. J. 2011, 188:243-245.
30. Mun-Bryce S., Rosenberg G.A. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1998, 274:1203-1211.
31. Nagase H., Woessner J.R.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274:21491-21494.
32. Noli C. Canine leishmaniasis. Waltham Focus 1999, 9:16-24.
33. Opdenakker G., Van den Steen P.E., Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001, 22:571-579.
34. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat. Rev. Mol. Cell Biol. 2007, 8:221-233.
35. Pul R., Kopadze T., Skripuletz T., Voss E.V., Kieseier B.C., Stangel M. Polyclonal immunoglobulins (IVIg) induce expression of MMP-9 in microglia. J. Neuroimmunol. 2009, 217:46-50.
36. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 2008, 75:346-359.
37. Revest M., Donaghy L., Cabillic F., Guiguen C., Gangeux J. Comparison of the immunomodulatory effects of L. donovani and L. major excreted-secreted antigens, particulate and soluble extracts and viable parasites on human dendritic cells. Vaccine 2008, 26:6119-6123.
38. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 2002, 39:279-291.
39. Rosenberg G.A., Estrada E.Y., Dencoff J.E., Hsu C.Y. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998, 29:2189-2195.
40. Santarém N., Silvestre R., Tavares J., Silva M., Cabral S., Maciel J., Cordeiro-Da-Silva A. Immune response regulation by Leishmania secreted and nonsecreted antigens. J. Biomed. Biotechnol. 2007, 2007:1-10.
41. Sellner J., Leib S.L. In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation. Neurobiol. Dis. 2006, 21:647-656.
42. Slappendel R.J., Ferrer L. Leishmaniasis. Clinical Microbiology and Infectious Diseases of the Dog and Cat 1998, 450-458. WB Saunders, Philadelphia. C.E. Greene (Ed.).
43. Strazielle N., Khuth S.T., Murat A., Chalon A.L., Giraudon P., Belin M.F.O., Ghersi-Egea J.-F.O. Pro-inflammatory cytokines modulate matrix metalloproteinase secretion and organic anion transport at the blood-cerebrospinal fluid barrier. J. Neuropathol. Exp. Neurol. 2003, 62:1254-1264.
44. Sulik A., Wojtkowska M., Oldak E. Preanalytical factors affecting the stability of matrix metalloproteinase-2 concentrations in cerebrospinal fluid. Clin. Chim. Acta 2008, 392:73-75.
45. Van den Steen P.E., Van Aelst I., Starckx S., Maskos K., Opdenakker G., Pagenstecher A. Matrix metalloproteinases, tissue inhibitors of MMPs and TACE in experimental cerebral malaria. Lab. Invest. 2006, 86:873-888.
46. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92:827-839.
47. Webster N.L., Crowe S.M. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J. Leukoc. Biol. 2006, 80:1052-1066.
48. Will H., Atkinson S.J., Butler G.S., Smith B., Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase a and initiates autoproteolytic activation. J. Biol. Chem. 1996, 271:17119-17123.
49. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998, 21:75-80.